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Abstract 
Human -defensin 2 (HBD2) has been shown to interact with pathogenic bacteria and components of the 
mammalian innate and adaptive immune response. We describe a quick and reliable method for the 
production of HBD2 in Escherichia coli. HBD2 was expressed as an insoluble fusion, chemically cleaved and 
oxidised to give a single, folded HBD2 -isoform. The purified peptide was analysed by high resolution mass 
spectrometry, displayed a well-dispersed 
1
H NMR spectrum, was a chemoattractant to HEK293 cells 
expressing CCR6 and acted as an antimicrobial agent against E. coli, P. aeruginosa and C. albicans. 
 
Introduction 
Antimicrobial peptides (AMPs) are essential components of the innate immune response and act as the first 
line of defence against invading pathogens 
[1]
. The AMP family displays enormous sequence, structural and 
functional diversity and over 900 different eukaryotic peptides have been characterized to date (sequences are 
available in the Antimicrobial Sequences Database (AMSDb), http://www.bbcm.univ.trieste.it/). Defensins are 
a subset of the AMP family and are small (3-5 kDa), cationic peptides that play roles in both innate and 
adaptive immunity 
[2-7]
. They are characterised by 6 conserved cysteine residues that form 3 disulfide bonds 
and are divided into two main subfamilies; alpha (-) and beta (-) are defined by their cysteine spacing, 
disulfide bond connectivity and genomic organisation. The -defensins display Cys1–Cys6, Cys2-Cys4, Cys3-
Cys5 S-S connectivity and contain ~29-35 residues, whereas the -defensins display a S-S connectivity of 
Cys1-Cys5, Cys2-Cys4, Cys3-Cys6 and consist of ~40-50 residues. A third subfamily, the -defensins also 
contain 3 S-S bonds but are cyclic peptides, fused at the N- and C-termini, and have only been found in rhesus 
monkeys. 
Analysis of the human genome revealed the presence of considerably more -defensin genes than previously 
thought 
[8]
. In contrast, only 6 human -defensins have been identified [9] and elegant studies of the structures 
and properties of these peptides (HNP1-4 and HD5 and HD6) by a number of research groups have begun to 
provide a better understanding of their role in the immune response 
[7,10-14]
. The high resolution structures of a 
few of the known mammalian -defensins have been determined by NMR spectroscopy and x-ray 
crystallography and include bovine neutrophil BD-12, penguin spheniscin and the human -defensins (HBD1, 
HBD2, HBD3) 
[15-22]
, but more work is needed to explore the structure/functional relationship of this sub-
family. We have chosen HBD2 as a target; it was shown that this defensin is expressed in epithelial cells and 
in the epidermis, and was originally isolated from human psoriatic scales 
[23]
. It is expressed as a 64 amino 
acid precursor peptide and the mature form consists of 41 residues with a net positive charge of +7. The 3D 
structure of mature HBD2 revealed an amphipathic molecule with distinct patches of positively-charged and 
hydrophobic residues 
[17,19,20]
. It is thought that this topology allows the defensin to interact with the outer cell 
components of bacterial membranes and act as a potent antimicrobial peptide against a range of pathogens 
[24]
. 
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Recent studies have shown that a number of defensins and their related peptide fragments, can act also as 
potent stimulators of the adaptive immune response, e.g. HBD2 acts as a chemoattractant for CD4 memory T 
cells and immature (but not mature) dendritic cells, by acting through the chemokine receptor CCR6, a 
member of the G-protein coupled receptor (GPCR) family 
[25,26]
. 
To study the molecular details of the interaction of HBD2 with its various targets we required a robust method 
for the production of single isoform material. The production of defensins suitable for structural and 
functional studies has been achieved by solid-phase peptide synthesis but the inherent amphiphilic nature of 
the peptide, protection strategies and losses upon oxidation have caused associated problems 
[27,28]
. As an 
alternative, recombinant methods have also been developed, e.g., Ganz and colleagues have used a 
baculovirus/insect cell system to produce active human peptides HNP-1, HD-5, HBD1 HBD2 
[29-32]
. As well 
as this method others have employed the common, easy-to-use host E. coli 
[33-36]
. Here however, there is the 
inevitable problem of toxicity of the defensins towards the host expression system but this has been overcome 
by expressing the peptide fused to a protein partner within inclusion bodies. This introduces a further cleavage 
step to release the mature peptide and results in low overall yield. The use of expensive proteases such as 
enterokinase also increases the cost of the overall production of sufficient quantities of peptide. New strategies 
such as using the yeast Saccharomyces cerevisiae as a host organism or production by a cell-free system have 
also emerged recently 
[37,38]
. These combined methods have allowed researchers to begin to explore the 
structure and activity of certain defensins 
[22,39-42]
. 
To produce defensins for a range of structural and functional studies, we describe a method for the production 
of recombinant, active, single isoform -HBD2 from an Escherichia coli host. We designed a codon-
optimised HBD2 gene for bacterial expression and synthesised this gene by recursive PCR 
[43]
 (Figure 1). and 
developed a protocol to isolate mature HBD2. This peptide was characterised by a range of structural 
techniques and was active in functional assays. 
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    AlwNI MetGlyIleGlyAspProValThrCysLeuLysSerGlyAlaIleCysHis 
1 CAGGCGCTGATGGGTATCGGTGACCCGGTTACCTGCCTGAAATCCGGTGCTATCTGCCAC 60 
GTCCGCGACTACCCATAGCCACTGGGCCAATGGACGGACTTTAGGCCACGATAGACGGTG 
 
  ProValPheCysProArgArgTyrLysGlnIleGlyThrCysGlyLeuProGlyThrLys 
61 CCGGTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCTGCGGTCTGCCGGGTACCAAA 120 
GGCCAAAAGACAGGCGCAGCAATGTTTGTCTAGCCATGGACGCCAGACGGCCCATGGTTT 
    
   CysCysLysLysPro*** AlwNI  
121 TGCTGCAAAAAACCGTGACAGATGCTG 147 
   ACGACGTTTTTTGGCACTGTCTACGAC   
(B) 
 
   1 MGSSHHHHHH SSGLVPRGSH AHTPEHITAV VQRFVAALNA GDLDGIVALF 
  51 ADDATVEDPV GSEPRSGTAA IREFYANSLK LPLAVELTQE VRAVANEAAF 
  101 AFTVSFEYQG RKTVVAPIDH FRFNGAGKVV SIRALFGEKN IHACQALMGI 
  151 GDPVTCLKSG AICHPVFCPR RYKQIGTCGL PGTKCCKKP 
(C) 
 
 
Figure 1. A. Schematic representation of expression vector pET-28a/HIS-KSI-HBD2. B. Design of synthetic, 
codon-optimized HBD2 gene (147 bp) for E. coli expression. Primers were designed for overlapping recursive 
PCR (see Table 1). The 5’ and 3’ primers incorporated AlwN1 restriction sites (bold) to allow cloning of KSI-
HBD2 fusion into pET28a. C. The full-length His-KSI-HBD2 fusion sequence (189 aa) with mature HBD2 
(41 aa) produced by CNBr cleavage after the Met residue highlighted in bold. The Met-Ala mutations in KSI 
(M1A and Met126A) are underlined. 
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Materials and methods 
Materials 
E. coli strains Top10 (Invitrogen) and BL21 (DE3) (Novagen) were used for construction of plasmids and 
expression of proteins respectively. Polymerase chain reaction (PCR) was carried out using Hercules 
polymerase (Stratagene) and puRe Taq Ready-To-Go PCR beads (GE Healthcare). PCR products were cloned 
initially in pGEM-T easy (Promega), then re-cloned into pET plasmids (Novagen). Site-directed mutagenesis 
used the Quick-change kit (Stratagene). Nickel-nitrilotriacetic acid (Ni-NTA) affinity resin was from Qiagen. 
Snakeskin dialysis tubing was from Pierce (3 kDa cut-off). Oligonucleotide primers were purchased from 
SigmaGenosys. All restriction enzymes and T4 DNA ligase were from New England Biolabs. Nu-PAGE 12% 
Bis-Tris pre-cast gels were from Invitrogen. HPLC columns were purchased from Phenomenex, synthetic 
human -defensin 2 (bHBD2, biotinylated at the N-terminus) was purchased from Albachem and Polymyxin 
B (PMB) was obtained from Calbiochem and tris(2-carboxyethyl)phosphine (TCEP) and CNBr were from 
Sigma. 
 
Synthesis and cloning of codon-optimized HBD2 
Six overlapping primers (Table 1) with codons optimized for expression in E. coli were designed using the 
mature HBD2 amino acid sequence (also known as DEFB4, Genbank accession number, NM_004942). The 
reaction contained in a final volume of 100 l: 10 l (100 pmol) of the outermost 5’ primers (P1 and P6) of 
each strand, 10 l (10 pmol) of the internal primers (P2 – P5), 4 l DMSO, 10 l 10 x Herculase reaction 
buffer (Stratagene), 1 l Herculase Hotstart DNA polymerase (Stratagene), 4 l 25 mM dNTPs, 21 l dH2O 
and was subjected to 30 PCR cycles of 95 ºC for 2 minutes, 40 ºC for 3 minutes and 72 ºC for 30 seconds. A 
second amplification was performed to confirm annealing of all six primers in a final volume of 50 l: 5 µl 
primer P1 (50 pmol), 5 l primer P6 (50 pmol), 2 l template, 38 l dH2O and 2 puRe Taq Ready-To-Go PCR 
beads were subjected to 30 PCR cycles of 95 ºC for 2 minutes, 40 ºC for 3 minutes, 72 ºC for 30 seconds and 
a final extension of 72 ºC for 10 minutes to add A overhangs. The PCR product (Figure 2A) containing the 
codon-optimized gene preceded by Met and flanking AlwN1 recognition sites was purified, cloned into 
pGEM-T Easy plasmid and a positive clone sequenced to confirm the fidelity of the insert. The target gene 
was then cut and ligated into the expression plasmid pET-31b (Novagen) to give pET-31b/HBD2. To 
incorporate a N-terminal His(6)-tag sequence, both pET-31b/HBD2 and pET-28a(+) vectors were cleaved by 
restriction enzymes NdeI and XhoI and the HBD2 fragment now containing the ketosteroid isomerase (KSI)-
fused gene was cloned into pET-28a (Figure 1A). To avoid CNBr cleavage at unwanted sites within the fusion 
residues Met 1 and 126 of KSI were replaced with Ala by site-directed mutagenesis to give plasmid pET-
28a/His-KSI-HBD2 (Figure 1 C). The fidelity of this clone was confirmed by DNA sequencing. 
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Figure 2. A. Synthesis of optimised HBD2 gene by recursive PCR. Lane 1, 1kb DNA Hyperladder I 
(Bioline); lane 2, recursive HBD2 PCR product. The band indicated by arrow is the 147bp codon-optimised 
HBD2 gene product. B. Expression of HIS-KSI-HBD2 in pET-28/HisKSI. 12 % Bis-Tris acrylamide gel 
analysis before and after induction with IPTG. Lane M, SeeBlue 2 protein marker (Invitrogen); lane 1, total 
bacterial lysate before induction; lane 2 insoluble fraction after induction (His-KSI-HBD2, Mr 20.2 kDa). 
 
Table 1. Primers used in synthesis of codon-optimised HBD2 
Primer Sequence (5’-3’) 
 
P1 
P2 
P3 
P4 
P5 
P6 
 
M1A For 
M1A Rev 
M126A For 
M126A Rev 
 
CAGATGCTGATGGGTATCGGTGACCCGGTTACCTGCCTGAAATCC 
CGGACAGAAAACCGGGTGGCAGATAGCACCGGATTTCAGGCAGGT 
CCGGTTTTCTGTCCGCGTCGTTACAAACAGATCGGTACCTGCGGT 
GCAGCATTTGGTACCCGGCAGACCGCAGGTACCGAT 
ACCAAATGCTGCAAAAAATGACAGATGCTG 
CAGCATCTGTCACGGTTTTTTGCAGCATTTGGTACCCGG 
 
GCGGCAGCCATGCGCATACCCCAGAACACATC 
GATGTGTTCTGGGGTATGCGCATGGCTGCCGC 
GAATATTCACGCATGCCAGGCGCTGATGGGTATCGGTGAC 
GTCACCGATACCCATCAGCGCCTGGCATGCGTGAATATTC 
 
Expression of KSI-HBD2 in E. coli 
The freshly transformed BL21 (DE3) colony containing the pET-28a/His-KSI-HBD2 plasmid was used to 
inoculate 250 mL of 2YT medium at 37 ºC, with shaking containing 30 g/mL kanamycin. This was grown 
for 12 hours and then added to 3 litres of 2YT, containing 30 g/mL kanamycin to give an OD600 0.1 and 
divided into six one litre flasks, with approximately 500 mL in each flask. Cells were grown at 37 ºC until an 
OD600 = 0.5, induced with a final concentration of 1 mM isopropyl--D-1-thiogalactopyranoside (IPTG), and 
incubated for a further 6 h. Cells were subsequently harvested by centrifugation (6000 rpm for 10 minutes, 
4 °C). 
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Isolation of KSI-HBD2 inclusion bodies and production of HBD2 
All centrifugation steps were carried out for 20 minutes at 11000 rpm and 4 ºC. The cell pellet containing 
highly expressed HisKSI-HBD2 was suspended in 5 mL/g in resuspension buffer (50 mM Tris, 25% sucrose, 
1 mM EDTA, 0.1% sodium azide, 10 mM DTT, pH 8.0), before addition of 50 mg/mL lysozyme, 500 mM 
MgCl2 and 10l DNase. After incubation for 30 minutes at room temperature, lysis buffer (50 mM Tris, 1% 
Triton X-100, 100 mM NaCl, 0.1% sodium azide, 10 mM DTT, pH 8.0) was added (5 mL/g wet weight 
original pellet) and incubated for 45 minutes at room temperature. To this cloudy suspension, EDTA (500 
mM) was added to give a final concentration of 1 mM, and the sample was snap-frozen in liquid N2 before 
immediately thawing for 30 minutes in a 37 ºC water bath. To this thawed extract, MgCl2 (500 mM) was 
added to give a 1mM final concentration and the sample was incubated at room temperature for 1 h to allow 
the viscosity to decrease before centrifugation. The supernatant was discarded and the pellet from this step 
was resuspended in an appropriate volume of buffer (50 mM Tris, 1% Triton X-100, 100 mM NaCl, 1 mM 
EDTA, 0.1% NaAzide, 1 mM DTT, pH 8.0), sonicated for 4 x 30 second blasts and centrifuged. The resulting 
pellet was then washed in 1 M Guanidine HCl buffer (1 M GuHCl, 50 mM Tris, 1% Triton X-100, 100 mM 
NaCl, 1 mM EDTA, 0.1% sodium azide, 1 mM DTT, pH 8.0), sonicated with 4 x 30 second bursts and 
centrifuged. The resulting pellet (inclusion bodies containing highly enriched KSI-HBD2) was resuspended in 
~ 50ml 6 M GuHCl binding buffer (6 M GuHCl, 50 mM Tris, 10 mM imidazole, 500 mM NaCl, 5 mM -
mercaptoethanol, pH 8.0). These inclusion bodies were added to 10 ml pre-equilibrated nickel-nitrilotriacetic 
acid (Ni-NTA, Qiagen) agarose affinity resin, mixed by rotation for 1 h at 4 
o
C, then decanted into an empty 
25 ml column reservoir. The packed resin was washed with 6 M GuHCl binding buffer (50 ml) and then 
eluted with 25 ml of elution buffer (6 M GuHCl, 50 mM Tris, 120 mM imidazole, 500 mM NaCl, 5 mM -
mercaptoethanol, pH 8.0). This elution step with 120 mM imidazole was then repeated to give 50 ml of 
purified HisKSI-HBD2. The eluted fusion protein was dialyzed against 25 mM Tris buffer, pH 8.0 overnight 
at 4 
o
C which caused precipitation of the fusion protein. 
The fusion was recovered by centrifugation and the pellet was resuspended in 6 M GuHCl, 25 mM Tris 
buffer, pH 8.0. To this HCl (5 M stock) was added until the pH was ~1.0. Solid CNBr was added to give a 
final concentration of 250 mM and cleavage was allowed to proceed for 24 h in the absence of light and under 
nitrogen. The cleaved mixture was evaporated at 42 
o
C using a rotary evaporator to remove any unreacted 
CNBr, and the concentrated sample was dialyzed against 25 mM Tris buffer, pH 8.0 overnight at 4 
o
C to cause 
precipitation of the KSI. The precipitate was removed by centrifugation and the supernatant containing HBD2 
was filtered (0. 45 M) and purified  
by RP-HPLC as described below. 
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Purification of HBD2 
Preparative RP-HPLC on a Jupiter™ Proteo column was performed with a Waters 600 control pump fitted 
with a photodiode array 996 detector using Millenium 32 software. The HBD2 isolated from the CNBr 
cleavage step was applied to the column in 3-4 ml batches, the column was washed with 5% acetonitrile then 
a linear gradient of 5-55% acetonitrile over 50 minutes at a flow rate of 3 mL/minute was used to elute the 
HBD2. Fractions were analysed by SDS-PAGE and those containing HBD2 were pooled and shown to be a 
mixture of partially reduced and oxidized peptides (by ESI-mass spectrometry). 
 
Oxidation of recombinant HBD2 
The HBD2 recovered by prep-HPLC was freeze-dried then reconstituted in 25 mM Tris, pH 8.0, with 20 mM 
tris(2-carboxyethyl)phosphine (TCEP) added to convert the peptide to the fully reduced form before re-
purification by prep-HPLC using identical conditions as above. Fractions containing HBD2 were freeze-dried 
then dissolved in 50 mM Tris, pH 8.0, 3 mM cysteine, 0.3 mM cystine and stirred for 4 h at room temperature. 
The reaction was followed by analytical RP-HPLC and analyzed by ESI-mass spectrometry to confirm that 
the HBD2 was present in the oxidized form (elution at 40 mins). The final yield of oxidized -HBD2 is 3-6 
mg from 3 litres of E. coli culture (based on 10 preparations). 
 
Western blot analysis 
Peptides were separated on a 12% Bis-Tris gel as described by the manufacturer (Invitrogen) followed by 
electroblotting using a Trans blot SD Semi-Dry Transfer cell (Bio-Rad) onto a Hybond-ECL nitrocellulose 
membrane (GE Healthcare). HBD2 was detected with a HBD2-specific antibody (Autogen Bioclear) and 
electrochemiluminescence plus (ECL
+
) using a Streptavidin-HRP antibody according to the manufacturer’s 
instructions (GE Healthcare). 
 
Disulfide bond connectivity 
The disulfide bond connectivity of the oxidized HBD2 was determined by trypsin/chymotrypsin digest, 
Edman degradation and mass spectrometry analysis as described previously 
[40,44]
. 
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1D 
1
H NMR Spectrum 
1 mg of oxidized HBD2 was dissolved in 20 mM sodium acetate buffer, pH 4.0 at 25 
o
C and 10% D2O (v:v) 
was added to give to a final peptide concentration of 0.46 mM. The 
1
H NMR spectrum was recorded on a 
Bruker AVANCE spectrometer equipped with a cryoprobe operating at 600 MHz and 25 °C. 128 scans were 
taken with a sweep width of 15 ppm and 8000 complex points. For water suppression double-pulsed gradient 
spin echo was used. 
 
Antimicrobial activity assay 
The purified, oxidized HBD2 was dissolved into 0.01% acetic acid and centrifuged (13000 rpm for 10 
minutes, 25 °C) to remove precipitate. The HBD2 was concentrated (Vivaspin 0.5 mL concentrator, 3000 
MWCO PES) to 1 mg/mL and stock HBD2 solutions of concentrations 15, 30, 60, 125, 250 and 500 μg/mL 
were prepared. Antimicrobial assays were carried out according to the method set out in our previous study 
[25,40,45]
. Briefly, a laboratory strain of E. coli K-12 MG1655 was grown to midlogarithmic phase (OD at 
600nm = 1.0). From this 90 l E. coli (~1.0 x 105 cells) was incubated with 10 l of each stock HBD2 solution 
and as a negative control 90 l E. coli was incubated 10 l 0.01% acetic acid. These samples were incubated 
at 37 °C for 2 hours. Then 10-fold serial dilutions of
 
the incubation mixture were plated on Iso-Sensitest 
plates,
 
incubated at 37 °C, and the CFU was determined the following
 
day. Colonies were counted and the 
LD50, LD90 (Lethal Dose: amount of peptide required to kill 50 % and 90% of viable cells) and the MBC99.99 
(Minimum Bactericidal Concentration at 99.99 %) values were calculated from the resulting killing curve. 
The same antimicrobial assays were performed with Pseudomonas aeruginosa (PAO1), a Gram-positive strain 
Staphylococcus aureus (ATCC 25923) and a fungus, Candida albicans (J2922) 
[45]
. In parallel, the same 
strains were used with the antimicrobial agent Polymyxin B (PMB) as a control. All the killing assays were 
performed at least 3 times for each strain and the values were obtained by taking
 
the mean of each 3 
experiments.  
 
High resolution FT-ICR mass spectrometry 
The oxidized HBD2 was diluted to a final concentration of 1 µM in electrospray buffer, consisting of 50:50 
methanol:H2O with 0.2 % formic acid. Data was acquired on a 12 Tesla Apex Qe FT-ICR (Bruker Daltonics, 
Billerica, MA) equipped with mass resolving quadrupole, coupled to a nano-electrospray ionization (nESI) 
enabled TriVersa Nanomate (Advion Bioscience, Ithaca, NY). Samples were infused at a flow rate of 50 
nanolitres per minute. Desolvated ions were transmitted to a 6 cm Infinity cell

 penning trap. Trapped ions 
were excited (frequency chirp 48-500 kHZ at 100 steps of 25 s) and detected between m/z 600 and 2000 for 
1 s to yield broadband 1 Mword time-domain data. Each spectrum was the sum of 64 mass analyses. Typical 
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chamber base pressure was ~9 x 10
-11
 mbar. Time-domain FT-ICR data was acquired using an AQS console 
and the aquisition rate was typically ~1 scan/2 s. Fast Fourier Transforms and subsequent analyses were 
performed using DataAnalysis (Bruker Daltonics, Billerica, MA). 
 
Chemotaxis assay 
The chemotaxis activity analysis was carried out against HEK293 cells expressing CCR6 as we have 
previously reported 
[25]
. The migration of CCR6-transfected human embryonic kidney HEK293 cells was 
assessed with a microchemotaxis chamber technique. Chemotactic activity was measured as the optimal 
concentration of test compound at which the highest chemotactic index value was obtained. Experiments were 
carried out three times. CCL20 (also known as MIP3-) was from Peprotech (London, UK). 
 
Results and discussion 
Synthesis of HBD2 gene by recursive PCR 
Our goal was to produce mature, untagged HBD2 as a single -defensin isoform. Our strategy to enhance the 
expression of the toxic human antimicrobial peptide HBD2 in the host E. coli was to fuse it to the highly 
insoluble ketosteroid isomerase (KSI) tag using a commercially available plasmid. Six overlapping primers 
(Table 1) with codons optimized for expression in E. coli were designed to synthesise the HBD2 gene in a one 
step recursive PCR reaction 
[43] 
(Figure 1B). An ATG Met codon was incorporated at the 5’ end of the HBD2 
gene to enable cleavage of the peptide from the KSI tag by cyanogen bromide (CNBr) (Figure 1B). A similar 
chemical cleavage strategy had been used by Ganz and coworkers to produce active HBD2 expressed in 
baculovirus-infected insect cells 
[29]
. Restriction sites for AlwNI, flanking the HBD2 sequence, were 
engineered into the gene to enable cloning into the KSI expression plasmid, pET-31b and a stop codon was 
engineered upstream of the 3’ AlwNI site to avoid generation of a homoserine lactone HBD2 derivative after 
cleavage. Initial PCR gave a gene product at the expected size of the HBD2 target (144bp, Figure 2A) and a 
second PCR amplification using this template with the 5’ and 3’ terminal primers gave a gene that was cloned 
firstly into plasmid pGem-T Easy then into the expression plasmid pET-31b digested with the same enzyme. 
To utilize His-tag purification technology, the KSI-HBD2 fusion gene was excised from pET-31b and ligated 
into pET-28a downstream of a 6xHis-tag. To improve the efficiency of the chemical cleavage and generate a 
single CNBr cleavage site within the KSI-HBD2 fusion, the Met1 and Met126 residues within the KSI gene 
were converted to Ala by site-directed mutagenesis to generate the expression plasmid pET-28a/His-KSI-
HBD2 which was used for all further studies (Figure 1A). 
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Expression of His-KSI-HBD2 
Plasmid pET-28a/His-KSI-HBD2 was used to transform BL21 (DE3) cells and on a small scale (10ml) 
induction with IPTG, a strong band corresponding to His-KSI-HBD2 at 20.2 kDa was observed by SDS-
PAGE in agreement with the predicted molecular weight of the KSI-HBD2 fusion protein of 189aa (Figure 
2B). This expression was scaled up to 3 litres of culture medium and yielded ~9 g wet weight cell paste that 
was frozen at -20 C. 
 
Purification of His-KSI-HBD2 and cleavage of HBD2 
The His-KSI-HBD2 fusion was isolated from the bacterial pellet by a series washing and centrifugation steps. 
Aliquots were removed throughout the purification protocol and analysed by SDS-PAGE to monitor the 
increased purity and yield of His-KSI-HBD2. We engineered a methionine residue at the N-terminus of the 
HBD2 protein to allow cleavage from the KSI tag by CNBr. This non-enzymatic cleavage is efficient and less 
expensive than using proteolytic enzymes such as enterokinase. After a one-step Ni-NTA affinity purification, 
the His-KSI-HBD2 was sufficiently pure for CNBr cleavage (Figure 3A). After 18-22 h, the cleavage was 
complete and separation of the fusion protein from HBD2 was carried out by dialysis against buffer (25 mM 
Tris, pH 8.0) followed by centrifugation (10,000 r.p.m.) to remove any precipitate. Cleaved HBD2 was shown 
to be in the soluble fraction by SDS-PAGE (Figure 3A). 
 
 
(A) 
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(B) 
 
(C) 
Figure 3. Purification of recombinant HBD2 A. 12 % Bis-Tris acrylamide gel analysis of HIS-KSI-HBD2 
fusion (lane 1) and recovered, soluble HBD2 after CNBr cleavage (lane 2) (M, SeeBlue 2 marker 
(Invitrogen)). B. Western blot of oxidized HBD2 probed with anti-HBD2 antibody (Lane 1, Oxidised HBD2 
(2.5 g); lane 2, Synthetic biotinylated bHBD2 (1 g)). C. Reverse-phase HPLC chromatograms of reduced 
HBD2 (upper trace, ~34 mins) and oxidized HBD2 (lower trace, ~38 mins). 
 
Characterisation of oxidized, folded -defensin HBD2 
Soluble HBD2 was purified by preparative RP-HPLC and mass spectrometry showed that it was a mixture of 
reduced and oxidized forms. This HBD2 mixture was completely reduced using TCEP then purified by RP-
HPLC. The recovered HBD2 was oxidized at room temperature using a cysteine/cystine redox buffer. The 
fully oxidized form has a longer retention time (~4 minutes) compared to the reduced form (Figure 3C) in 
agreement with previously published data 
[44]
. This peptide was reactive in a Western blot assay with anti-
HBD2 antibody that confirms the identity of the purified HBD2 (Figure 3B). High resolution FT-ICR mass 
spectrometry was used to determine the accurate mass of HBD2 and confirm its oxidation state. The HBD2 
HBD2 bHBD2 
1 2 
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ionized efficiently displaying three charge states (+3, +4 and +5) and the isotopic distribution for the +4 
charge state and mass fit to those predicted for fully oxidised HBD2 with an elemental composition 
(C188H305N55O50S6) and average mass of 4328.23 Da (Figure 4). After purification and freeze drying, ~3-6 mg 
of fully oxidised -HBD2 was obtained. The 1D 1H NMR spectrum shows sharp, well-dispersed peaks in the 
amide region, which is indicative of a folded structure (Figure 5). Furthermore, it was important to carry out 
trypsin/chymotrypsin digest and Edman degradation analysis which showed that the peptide displayed the -
defensin (1-5, 2-4, 3-6) connectivity (data not shown). 
 
(A) 
 
(B) 
Figure 4. FT-ICR high resolution mass spectrometry analysis of recombinant HBD2. A. The ion envelope for 
nanospray FT-ICR analysis of oxidized HBD2 showing the +5 to +3 charge states. B. The isotopic envelope 
of the +4 charge state of oxidized HBD2. Closed circles represent the theoretical envelope expected from a 
[M+5H]5+
[M+4H]4+
[M+3H]3+
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HBD2 monomer with all cysteines reduced and the closed triangles represent that expected from a fully 
oxidized HBD2 with 3 S-S bonds. 
 
 
 
Figure 5. 1D 
1
H NMR spectrum of oxidized HBD2 in 20 mM sodium acetate buffer pH 4.0 and 10 % D2O on 
a Bruker AVANCE spectrometer equipped with a cryoprobe operating at 600MHz and 25 C. Only the amide 
proton region is shown for clarity. 
 
Antimicrobial and chemotactic activity of recombinant HBD2 
Fully oxidised HBD2 was dissolved in 0.01% acetic acid and the sample was concentrated to 500 g/mL for 
the assay. We analysed the activity of the fully oxidised HBD2 against E. coli K-12 MG1655, P. aeruginosa 
PAO1, S. aureus ATCC 25923 and C. albicans J2922 using a previously published assay 
[25,40,45]
. Values of 
LD50, LD90 and MBC99.99 values against 1 x 10
5
 cells were determined (Table 2). HBD2 was found to be 
effective in killing Gram-negative bacteria (E. coli and P. aeruginosa) and yeast C. albicans in the µM range, 
but showed a lower bactericidal effect toward Gram-positive S. aureus. These results are in good agreement 
with that of the natural sample
[23]
, the recombinant HBD2 preparations from other groups 
[29,46]
 and peptide 
prepared by solid-phase peptide synthesis 
[47]
 (Table 2). 
Yang and colleagues discovered that many defensins are potent chemotactic agents against a range of cells 
from the mammalian immune system including dendritic cells and T cells 
[26]
. The exact nature of the 
molecular interactions between HBD2 and the CCR6 receptor are presently unknown but a recent analysis of 
HBD1/CCR6 has begun to explore the residues involved 
[22]
. It was shown that HBD2 was active in 
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chemotaxis assays against CCR6, a GPCR previously been shown to be activated by the chemokine CCL20 
(MIP3-). We tested our recombinant HBD2 against HEK293 cells expressing CCR6 in an assay we have 
used in our laboratory 
[25]
 and found that it had optimal activity at 100 ng/ml (Figure 6). 
 
Table 2. Comparison of antimicrobial activity of HBD2 with previous studies (values are in µg/mL, PMB: 
Polymyxin B as control AMP). 
Strain Source MBC99.99
a
/MIC
b 
LD90
c 
LD50
d 
E. coli K12-MG1655 
E. coli ML-35 
E. coli  
E. coli ML35p 
This paper 
47 
23 
29 
MBC99.99<20 
a
 (<1.5
 a
, PMB) 
17
 b
 
 
3-6 
 
~10 
4.25-12.25
 f
 
<1.5 
 
P. aeruginosa PAO1 
P. aeruginosa ATCC 
27853 
P. aeruginosa 
P. aeruginosa ATCC 9027 
This paper 
47 
23 
29 
<25
 a
 (<1.5
 a
, PMB) 
17
 b
 
 
<3 
 
~10 
4.25-12.25
 f
  
<1.5 
 
 
C. albicans J2922 
C. albicans 
C. albicans 
C. albicans 820 
This paper 
47 
23 
29 
>50
 a
 (<3
 a
, PMB) 
70
 b
 
 
>6 
 
25 
4.25-12.25
 f
 
>1.5 
S. aureus ATCC 25923 
S. aureus 710A 
S. aureus  
S. aureus ATCC 6341 
This paper 
47 
23 
29 
>50
 a
 (6
 a
, PMB) 
35-70
 b
 
100
 e
 
N.D.
 e
 
>12 
 
>3 
a 
MBC99.99 values are the minimum concentration of peptide required to kill 99.99% of initial inoculum. 
b 
MIC values are the lowest concentration of peptide that will inhibit the visible growth of a microorganism. 
c 
LD90 values are the concentration of peptide required to kill 90% of initial inoculum. 
d
 LD50 values are the concentration required to kill 50% of initial inoculum. 
e 
Bacteriostatic effect. 
f 
Bactericidal effect. 
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Figure 6. Chemotactic activity of HBD2. The graph shows the number of HEK293 cells expressing the 
human chemokine receptor CCR6 that migrate towards the peptides. The number of cells per high power field 
(No./HPF) under the microscope is given. Chemotaxis medium is the control, CCL20 (also known as MIP-3) 
is the known chemokine ligand of CCR6. Each assay was repeated three times, numerical data are means ± 
S.D. and columns with an asterisk indicate peptide with significant activity (p<0.05) above culture medium. 
 
Conclusion 
The method described in this paper is straight forward and low-cost, allowing for the production of milligram 
amounts of -defensin HBD2 in a commonly-used E. coli host. The mature form of HBD2 was isolated as a 
single, homogenous, oxidized isoform with -defensin S-S bond connectivity. This HBD2 was an active 
chemokine for cells expressing the GPCR receptor CCR6 and a potent antimicrobial peptide against a range of 
microbes. It displayed excellent structural properties (NMR spectroscopy and high resolution mass 
spectrometry) and is suitable for future analysis of HBD2 in complex with a range of biological targets. The 
expression clone is also su itable for generation of a range of mutant defensins. 
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